Keynote, Product Demonstration
DJ Kleinbaum
- The company anticipates developing a platform by the end of Q1 to enable remote experiment design and execution at its South San Francisco central facility, where users will receive data and ancillary variables after the instrument runs autonomously.
- Full automation is planned such that scientists require no physical oversight, with experiments entering a queue to run on one of the company's instruments within 48 hours of submission to support rapid exploration of possibilities.
- Founders project that the initial funding will suffice to build a system that renders scientists significantly more efficient than those at major pharmaceutical or biotech firms through total automation.
- The platform is designed to eventually feature "push-button reproducibility" by robotically capturing all scientifically relevant variables and utilizing a strict ontology to ensure data consistency and searchability across different instruments.
- Over the course of approximately one to one-and-a-half years, the company intends to convert its internal tools into an externally accessible global product while teaching all hired scientists, including organic chemists and molecular biologists, the Wolfram language to build custom tools.
- The internal data system is expected to evolve to include protocols as data points, creating a workflow where personnel only visit to set up materials while running experiments from remote desks.
- The facility will operate as a production environment with rigorous controls and maintenance data to support high volumes of experiments, distinct from the capabilities of single-run labs.
- Capacity will be slowly ramped up in the coming months to accommodate an increasing number of scientists online as the system grows in functionality to accelerate research.
- The company commits to faithfully executing submitted experiments and ensuring all instruments operate nominally to maintain the utility of the service.
- The startup is currently in the early stages of development, having just begun onboarding scientists, with no specific material financial targets or risk disclosures detailed beyond the sufficiency of initial funding.